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Abstract. The term Bpatient centered,^ Bpatient centric,^ or Bpatient centricity^ is
increasingly used in the scientiﬁc literature in a wide variety of contexts. Generally, patient
centric medicines are recognized as an essential contributor to healthy aging and the overall
patient’s quality of life and life expectancy. Besides the selection of the appropriate type of
drug substance and strength for a particular indication in a particular patient, due attention
must be paid that the pharmaceutical drug product design is also adequately addressing the
particular patient’s needs, i.e., assuring adequate patient adherence and the anticipate drug
safety and effectiveness. Relevant pharmaceutical design aspects may e.g., involve the
selection of the route of administration, the tablet size and shape, the ease of opening the
package, the ability to read the user instruction, or the ability to follow the recommended (in-
use) storage conditions. Currently, a harmonized deﬁnition on patient centric drug
development/design has not yet been established. To stimulate scientiﬁc research and
discussions and the consistent interpretation of test results, it is essential that such a deﬁnition
is established. We have developed a ﬁrst draft deﬁnition through various rounds of
discussions within an interdisciplinary AAPS focus group of experts. This publication
summarizes the outcomes and is intended to stimulate further discussions with all
stakeholders towards a common deﬁnition of patient centric pharmaceutical drug product
design that is useable across all disciplines involved.
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INTRODUCTION
People are continuously at risk of developing acute or
chronic diseases that can signiﬁcantly affect their lives. While
the prevalence of individual diseases changes over the course
of life, the majority of diseases can occur at any life stage,
either alone or in conjunction with other diseases (1).
Over the past decade, tremendous progress has been
made in understanding a wide range of diseases both at the
genotype and phenotype levels (2). The acquired knowledge
has supported the introduction of new drug therapies to
improve therapeutic outcomes as well as to tackle life-
threatening diseases for which no therapy previously existed.
The overall increase in life expectancy due to advances in
pharmacotherapy, hygienic measures, healthcare, and wealth
contributes to an increase in the number and type of special
patient populations (3). Examples of these patients include
the very old, frail and multi-morbid, the long-term cancer
survivor, and the cognitively impaired (dementia). Analogous
to the pediatric population, these special elderly patient
populations will differ from the traditional adult population,
e.g., with respect to their clinical presentation and physical,
physiological, or psychological patterns. However, the collab-
oration and active participation of patients with common and
special characteristics is one of the inevitable aspects to
achieve safe and effective drug therapy and use, enabled not
least by an appropriate design of the drug product.
The ability of patients to adhere to a recommended
therapy may require speciﬁc skills and capabilities. When
these skills and capabilities are not present, patients may alter
their approach resulting in inappropriate drug use, improper
administration, poor adherence, or discontinuation of medi-
cation therapy altogether. In some cases, these patients rely
on support from caregivers to manage their medications.
Generally, medication management becomes more demand-
ing as the number of drug products, dosage forms, and dosing
moments increases. This situation likely contributes to
discrepancies in the safety and efﬁcacy of a drug in Breal^
patients after product launch relative to the safety and
efﬁcacy seen in well-controlled clinical trials.
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This potential discrepancy is not surprising when one
considers that most randomized clinical trials (RCT) are
focused on assessing the efﬁcacy and safety proﬁle of drugs
used to treat chronic conditions in relatively homogeneous
samples of patients that often exclude patients with relevant
co-morbidities, disabilities, and impairments (4). The estima-
tion of risks and beneﬁts of a drug treatment is therefore
based on the average effects of treatments in these random-
ized patient populations, and is likely not inclusive of the
variability in responsiveness to treatment and vulnerability to
adverse effects of all patients and patient populations to
whom the drug will be prescribed after approval. The
resulting approved drug product may not provide the desired
individual risk/beneﬁt proﬁle, and this risk must be consid-
ered in the overall therapeutic decision for the patient’s
acceptability of and success with a speciﬁc drug therapy (5,6).
Knowledge in pharmacology, pharmacodynamics, phar-
macokinetics, and food and drug interactions has increased as
well. Consequently, user instructions (product label, package
insert, and summary of product characteristics) have become
more precise regarding the intended use of drug products,
e.g., target age groups, dosing regimens, in-use stability, and
administration approaches. A therapeutic intervention of
three or more drug products is generally characterized by
the use of products for multiple conditions, with each
requiring a speciﬁc dosing strategy. The scheduling of such
strategies may be a highly demanding task affecting the risk
for dosing and administration errors. This risk is increased
when restrictions or special dosing requirements are present,
be such a dosing with or without food. Moreover, patients
with multi-morbidity and increased healthcare needs are also
at higher risk of functional and cognitive impairments, further
reducing their capability in managing complex tasks (7–9).
The interface between the patient and each drug product
within the holistic personal and environmental context is a
critical factor in the patient’s ability to follow the recom-
mended use instructions and to realize the expected thera-
peutic outcome with the same risk of side effects. While the
individual personal and environmental context varies from
patient to patient, there are several known common traits in
speciﬁc patient populations. The patient’s skills, capabilities,
co-morbidities, disabilities, or impairments can actually serve
as predictors of potential medication problems and errors.
For example, patients with signiﬁcant manual dexterity
impairments may not be able to break a tablet by hand
(10,11) or access medication in a package. Anticipating the
patient characteristics of the target patient population and its
subsets at the time of product design and initial development
is likely to result in a drug product that addresses the needs of
patients in the real world, resulting in an improved therapeu-
tic outcome (12).
The term Bpatient centricity^ is currently used in a
variety of different contexts, e.g., communication with pa-
tients through digital platforms, exchange forums, or market-
ing; as a reference to patient monitoring or support systems;
and in the design and execution of clinical protocols or as a
descriptive word for drug products designed to meet the
speciﬁc needs of individual patients and patient populations.
The objective of this publication is to promote a
discussion on the deﬁnition of patient centric pharmaceutical
drug product design. The authors hope to identify and
present key patient, disease state, and product attributes
and discuss how these attributes can affect and inﬂuence
patient-product interaction. The currently proposed deﬁnition
may also serve further research aimed at providing guidance
to pharmaceutical scientists on the characteristics of a patient
centric drug product for a speciﬁc drug product and
indication.
DEFINITION PROCESS
In order to develop a deﬁnition for Bpatient centric
pharmaceutical drug product design,^ a group of ﬁve experts
from academia, industry and regulatory bodies, and the
authors convened monthly and took a stepwise approach to
develop a deﬁnition that should serve both scientiﬁc research
and product development purposes.
Initial discussions revealed that several ambiguous terms
were commonly used. Therefore, it was deemed necessary to
align the precise meaning of these terms and words. The
proposed deﬁnitions for these identiﬁed terms and words are
summarized in Table I.
The term Bpatient centric pharmaceutical drug product
design^ consists of two distinct terms, Bpharmaceutical drug
product design^ and Bpatient centricity.^ Therefore, it was
deemed appropriate to ﬁrst deﬁne these terms independently
from each other. During the deﬁnition process of these terms,
the boundaries of their deﬁnitions were clariﬁed.
The discussions ﬁrst focused on the most important and
unique considerations and sought to create a short yet
comprehensive one-sentence deﬁnition.
The combination of patient centricity and pharmaceuti-
cal drug product design leads to a more speciﬁc term, namely
Bpatient centric pharmaceutical drug product design.^ This
term describes an approach that directly aligns product
characteristics with patient characteristics for a therapeutic
goal in a targeted patient population(s), and requires an
appropriate deﬁnition that can be used consistently among
key stakeholders. The deﬁnition also addresses the require-
ment that human (patient) characteristics are considered in
the product design. In this sense, for example, a primary
package closure system should not only fulﬁll its functional
requirement of protecting the product against environmental
contamination and ensuring product stability but also incor-
porate requirements such as being easy to open and reclose
and/or facilitating accurate dose measurement by caregivers
and/or patients with limited manual dexterity, grip strength,
or visual capacity.
A thorough analysis was performed to detail these items
for consideration. As the analysis revealed that the identiﬁed
Bpatient needs^ were either associated with patient-related
characteristics or with drug product-related characteristics,
these characteristics were captured as they were discussed.
PROPOSED DEFINITIONS
The proposed one-sentence deﬁnitions of the three most
frequently used terms in the patient centric pharmaceuticals
discussion are summarized in Table II.
The term drug (medicine) is either used to refer to a
singular therapeutic entity or as a general term for the
portfolio of drug products from a speciﬁc company. The term
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(drug) product relates to a speciﬁc physical presentation of
the drug by a speciﬁc company. The term entails the type of
dosage form and its dose/strength/concentration and excipient
composition relevant to product design of the dosage form’s
primary, secondary, and tertiary packaging; its mode of use
and dosing frequency; any potential dosing devices or medical
devices; user information (product label, patient information
leaﬂet (PIL), summary of product characteristics (SmPC);
product name and appearance, both unpacked and in its
primary, secondary, or tertiary packaging; and any other
product- or user-related authorized information that is
delivered with the product or available in digital form
through the internet. For the sake of clarity, the term drug
product applies to newly developed, follow on, and generic
products.
In Table III, the major product- and patient-related
characteristics for consideration in a patient centric pharma-
ceutical drug product design and development process are
summarized.
Based on the deﬁnitions of “pharmaceutical drug prod-
uct” and Bpatient centricity,^ a patient centric pharmaceutical
drug product design spans from the basic concept of a
pharmaceutical drug product to the effectiveness of the
product in the hand of the patient and/or its caregivers. This
drug product-patient interface includes elements that lead to
the intended (re)action of the patients to use the product as
intended and prevent medication non-adherence (intentional)
and medication errors (unintentional). Patient centric phar-
maceutical drug product design, therefore, cannot solely be
based on scientiﬁc or technical theories but will have to
Table I. Glossary of the Terms Used During the Deﬁnition Process of Patient Centric Drug Product Design
Term Deﬁnition Reference
Efﬁcacy The extent to which an intervention provides beneﬁt under ideal conditions
(e.g., randomized clinical settings)
Eichler et al. 2011 (6)
Effectiveness The extent to which an intervention provides beneﬁt under the usual circumstances
of healthcare settings (e.g., in primary care patients)
Eichler et al. 2011 (6)
Multi-morbidity Co-occurrence of two or more chronic or acute diseases and medical conditions in
one person
Marengoni et al. 2009 (13)
Co-morbidity Combination of additional diseases beyond the index condition whereby the
co-morbidity might affect the index disease
Marengoni et al. 2009 (13)
Polypharmacy The concomitant use of ﬁve or more different medicines Nobili et al. 2011 (3)
Impairment Anomalies, defects, loss, or other signiﬁcant deviation in the body structure that
leads to a deviation from certain generally accepted population standards in the
biomedical status of the body and its functions
WHO 2001 (14)
Disability Umbrella term for impairments, activity limitations, and participation restrictions WHO 2001 (14)
Patient needs What patients—and the population as a whole—desire to receive from health care
services to improve overall health to provide the capacity to beneﬁt from health
care services
Asadi-Lari et al. 2004 (15)
Patient acceptability The ability and willingness of a patient to take a medicine as intended EMA Paediatric Guideline
2013 (16)
Dosing device A device or tool to measure the dose prior to or in preparation of the drug product
for administration (e.g., cup, dosing spoon, liquid measuring device, tablet splitter)
Administration device A device to assist in the administration of the recommended dose, e.g., dosing devices,
inhalation spacer, autoinjector
EMA Paediatric Guideline
2013 (16)
Medical device An instrument, apparatus, appliance, software, material, or other article, whether used
alone or in combination, intended for diagnostic and/or therapeutic purposes, e.g.,
nebulizer system. Note: a tablet splitter is not a medical device but a dosing device.
EMA 2007 (17)
Comprehensive
assessment
A methodology to assess patient characteristics like disease conditions, iatrogenic
illnesses, disabilities, impairments, polypharmacy, speciﬁc needs, and other
Onder et al. 2013 (18)
Table II. The Proposed One-Sentence Deﬁnition of the Three Terms
Terms One-sentence deﬁnition
Pharmaceutical drug product
design
• The design of the comprehensive presentation of the therapeutic entity to the end user (patient/caregiver/
health care provider) including the type of dosage form; formulation; dose; dosing frequency; primary,
secondary, and tertiary packaging; medical device; dosing devices; instructions for use (as in the SmPC/PIL/
product label); and other authority-approved patient support tools and programs.
Patient centricity • The recognition of the needs of an individual patient or distinct patient populations and their speciﬁc needs
as the focal point in the overall design of a medicine including the targeted patients’ physiological, physical,
psychological, and social characteristics.
Patient centric pharmaceutical
drug product design
• The process of identifying the comprehensive needs of individuals or the target patient population and
utilizing the identiﬁed needs to design pharmaceutical drug products that provide the best overall beneﬁt
to risk proﬁle for that target patient population over the intended duration of treatment.
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acknowledge the layperson’s response to the product design.
Therefore, testing the drug product design with the targeted
patient population, within their personal health and environ-
mental context, will be essential to developing high quality
patient centric drug products. One approach to achieving this
understanding would be to expand usability studies to the
domiciliary setting and institutions such as schools, nurseries,
etc. where appropriate. Alternatively, incorporating the
ability to collect this information in the design of the clinical
trial may be appropriate from certain patient populations and
disease states.
By utilizing the relevant patient and disease state
characteristics as well as understanding the desired therapeu-
tic outcomes, the product designer/developer can identify
rational design drivers. These design drivers, which are
derived from an intimate understanding of the target patient
population, can then be associated with speciﬁc design
outputs that are speciﬁc to the drug product to be developed.
It should be noted that the drivers and associated patient
needs may be addressed or affected by one or more product
design elements so that a one-to-one relationship is unlikely.
Frequently, conﬂict among design elements arises, and
decisions must be made regarding the overall risk beneﬁt
impact a particular design element may bring. This approach
to the pharmaceutical drug product design can be extremely
valuable in the conceptual or design phase of a new product.
Table IV illustrates the relationship between design inputs,
drivers, and outputs.
From Table IV, it is evident that the design drivers and
design inputs have to be derived from the targeted patient
Table III. Summary of Major Drug Product-Related and Patient-Related Characteristics for Consideration in a Patient Centric Pharmaceutical
Drug Product Design and Development Process
Product-related characteristics Patient-related characteristics
• Type of drug substance (drug proﬁle, desired effects, side effects, therapeutic
window, mechanism of action)
• Dose to therapeutic effect (required dose range for different patient populations;
need for small or larger dosing increments, dose ﬂexibility)
• Route of administration (oral, nasal, rectal, parenteral, …)
• Type of dosage form (tablet, capsule, solution, injection, …)
• Formulation characteristics (immediate release, modiﬁed release, tablet
size/shape/color,/strength/concentration/, excipient composition, …)
• Product strength/concentration
• Packaging (primary, secondary, tertiary)
• Dosing and administration devices (oral syringe, inhalator, …)
• Product recognition, identiﬁcation (appearance unpacked product and in its primary,
secondary, or tertiary packaging name, name…)
• Instructions for use (SmPC, PIL, labeling, others….)
○ Speciﬁc dosing requirements (e.g., before meal, not together with drug x, …)
○ Product stability
○ Storage conditions
○ In-use shelf life and storage conditions
○ Preparation steps to administration
○ Compatibility with diluents and other medicines where appropriate
○ Compatibility with food or drink
○ Industry-veriﬁed manipulations of the dosage form
• Developmental stage/age
○ Newborn, toddler, …
○ Organ and body functions (kidney, liver, lung …)
○ Social-emotional development
○ Way of living (alone, with spouse, with parents)
○ Access to caregivers
• PK/PD and physiological changes
(e.g., receptor density, kidney clearance, …)
• Visual impairment
○ Near acuity
○ Visual ﬁeld
○ Blindness
• Loss of hearing
• Swallowing impairment
○ Safe solid dose swallowing
○ Dysphagia
• Poor hand sensitivity
○ Control of movement
○ Control of strength
○ Sensing surfaces or temperature
○ Control of eye-hand coordination
• Motoric impairment
○ Grip strength
○ Pinch strength
○ Manual dexterity
○ Arm mobility (e.g., lift above head)
○ Difﬁculties walking
○ Bedridden
• Cognitive impairment
○ Mild dementia, memory loss
○ Information processing speed
(hearing, understanding)
• Health literacy
• Dentition
• Psychological issues
○ Adherence
○ Negative perception
○ Depressive disorders
• Disease state, co-morbidity
○ Experience of disease
○ Disease cluster
○ Disabilities
○ End point of disease progression
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Table IV. Summary of the Major Items Considered as Design Drivers, Their Related Design Inputs, and Respective Patient Needs
Design Drivers Design Inputs Design Outputs
Characteristics disease/condition • Disease-speciﬁc expression
• Multi- and co-morbidity
• Frailty
• Disease severity/burden
• Disease stage
• Individual drug/drug combination
• Individual drug dose accuracy
• Dose range
• Disease-speciﬁc disabilities
Characteristics drug substance/
physiology
• Developmental stage (maturation,
declining body functions)
• Oro-esophageal and GI transit
• Permeability
• Fat/water ratio
• Drug metabolism and clearance
• Homeostasis
• Reserves
• Flexible dose adjustment
• Appropriate dosage form
• Excipient safety/total amount of excipients
• Low adverse drug reactions
• Low intake/administration frequency
Characteristics drug therapy • Need for different types of dosage forms
• Availability of combination products
• Reimbursement
• Dose tracking
Characteristics drug product • Multiple and polypharmacy
• Therapeutic complexity
• Prescription guidelines
• Different dosage forms
• Possibility of product modiﬁcations
(manipulations)
• Range of trademarks
• Simpliﬁed regimen
• Appropriate dosage form
• Drug product identiﬁcation
• Drug product recall
• Dosing frequency
• Dosing moments
• Dispensing, substitution, and re-substitutions
• Reimbursement
• Dose tracking
Patient characteristics • Age, gender, socio-emotional development
• Mobility (travel)
• Perceived wellbeing
• Functional limitations (motoric, sensory,
cognitive)
• Health literacy (disease/therapy
understanding)
• Dehydration/malnutrition
• Motivation
• Psychological traits
• Remaining life time
• Living alone or with others
• Daily occupation (work, school)
• Social support and interaction
• Stress resistance
• Usability/ergonomics
• Self-explaining/intuitive use
• Drug product information
• Product identiﬁcation
• Swallowability
• Palatability (taste, smell, texture)
• Reminder
• Dosing frequency/moments
• Least number of units/drug products
• Feedback/communication/motivation
Medication management
(adherence and administration)
• Intended and non-intended non-adherence
• Therapy simpliﬁcation
• Pill boxes and compliance aids
• Hoarding
• Environment where the medication needs
to be prepared and taken
• Access/cost
• Co-medications and changing (generic)
prescriptions
• Identiﬁcation/differentiation outside packaging
• Dosing frequency/moments
• In-use stability (e.g., external Bpill box,^
airport scanning)
• Ease of storage
• Convenience of use (e.g., speciﬁc requirements
like before breakfast)
• Use discretion
• Portability
• Food effects
• Reﬁll reminders
• Harmonized labeling, naming elements,
product elements (e.g., packaging), or cue tags
Usability (handling, storage,
and disposal)
• Drug product appearance
• Drug product shelf life
• Drug product storage
• Drug product disposal
• Drug product packaging
• Dose measurement and preparation
• Dosing frequency
• Need for administration device
• Ability to self-administer with ease
• Need for help from caregiver
• Learned usage/experience
• Handling issues (e.g., round tablets roll off the table)
• Ergonomics
• Formulations enabling (easier) self-administration
• Refrigeration requirements
• Stability during use period
• Minimize waste (dose form, packaging)
• Mechanical stress stability of the product
• BPredicted usage^ (modiﬁcation by patient)
1051Defining Patient Centric Pharmaceutical Drug Product Design
population. Comprehensive assessments (e.g., comprehensive
geriatric assessments) are a key part in generating and
prioritizing the patient population-speciﬁc design drivers and
design inputs. This process requires the involvement of
different healthcare professionals (e.g., physicians, nurses,
caregivers, and pharmacists) in performing the assessment
and identifying the most important and appropriate design
outputs together with the concerned patient population (18).
For example, medicine M with active substance S is
marketed by a company C as four drug products: an
immediate release tablet 100 mg, 200 mg, 400 mg with a
break mark, and an oral solution 20 mg/ml. The initial dose is
20 to 60 mg/day for children from birth up to 5 years of age;
100 mg/day for children from 5 years; and 200 mg once or
twice daily for adults. The maintenance dose is 10–20 mg/kg
in several doses for all patient populations. The maximum
dose is 35 mg/kg/day for children up to 6 years, 100 mg/day
for children from 6 years old and 1200 mg for adults, all in
several doses. The four drug products enable all recom-
mended doses. However, it can be questioned if the speciﬁc
needs of individual patients are sufﬁciently addressed by this
portfolio, as an older person with swallowing difﬁculties in
need of the maximum dose would need to take 20-ml solution
thrice daily. A solution with a higher strength or a multi-
particulate formulation may further support the medicine’s
patient centric approach.
The oral solution is packed in a 100-ml brown glass
bottle with a closure that can be attached to an oral syringe as
the primary packaging. The solution is water-based. Besides
the active substance S, it contains a sweetener, preservative,
ﬂavor, and colorant. The bottle is labeled and stored in a
carton box as the secondary packaging. The label on the glass
bottle and outer box each carries the main product informa-
tion like name, drug substance, dose/strength/concentration,
indication, expiry date, and storage condition. The detailed
product information is captured in the PIL, and a paper
version of the PIL is packed with the glass bottle in the outer
carton box. The outer packaging does not include a dosing
device. Pharmacists are held responsible for delivering a
dosing device that allows accurate dosing of the individual
patient’s dose. Links to additional product information either
through a web site of a bar code APP might be printed on the
PIL or the box. Patients would beneﬁt from information on
the potential of tablet chewing, mixing, or crushing and the
joint intake with food or drink as these approaches may avoid
the intake of high volumes of the oral solution in patients with
swallowing difﬁculties
The concept of patient centricity intends to consider all
elements of product design affecting or addressing the speciﬁc
needs of the target patient population. These elements can be
derived from known patient characteristics including age, co-
morbidities, and functional limitations at the various stages of
the disease. Even though the speciﬁc expression and progres-
sion of a given disease may vary among individual patients,
the major disease effects, particularly at more advanced
stages of a disease, are normally quite similar. Main effects
are typically manifest in the sensory, motoric, cognitive, and
psychological domains and present in a similar way. For
example, cluster analysis provided evidence that patients with
hypertension suffer most from heart failure, atrial ﬁbrillation,
and cerebrovascular disease, while patients with diabetes
mellitus have a high likelihood for visual impairments and
deafness as co-morbidity (13). These predictable diseases and
patient-speciﬁc characteristics can be leveraged to improve
the drug product design by utilizing a Bpatient centric^
development approach.
DISCUSSION
The principles of patient centricity are being used in
conjunction with and to augment various healthcare inter-
ventions dedicated to improving their effectiveness for
patients. When considering the role of pharmacotherapy in
healthcare interventions, it is evident that the patient-drug
product interface is a critical part of the therapeutic process
that might lead to medication non-adherence or medication
errors (19). To achieve the desired outcome, patient factors
need to be considered and incorporated into the product
design. For medical devices, human factor studies are now
required to be incorporated into the development process to
ensure the device is able to be effectively used by the patient
or caregiver, and potential sources of use errors are mini-
mized (20). Drug products resulting from a Bpatient centric
development approach^ must aim to enhance the usability of
the drug products supporting the medicine’s safety, effective-
ness, and quality over the entire target patient population.
The effective use of drug products over the course of
treating a disease requires certain levels of disease under-
standing, therapeutic strategies, treatment requirements, and
patient or caregiver capabilities. These levels of understand-
ing and capability can be divided into skill-, rule-, and
knowledge-based information, and task processing. The
skill-based level refers to highly practiced and familiar tasks
that require only very little attention and are to a great extent
automatic behavior. The rule-based level requires some
consciousness as the information or task has to be derived
from a known rule that needs to be applied to the situation.
In cases where the information or task is new and no rules
can be applied, the task becomes knowledge-based, requiring
a higher level of capability to manage the unfamiliar situation
by identifying analogies with previous experience or use
higher-level knowledge and feedback from the environment
(21). While skill-based tasks are the lowest cognitive and
functionally demanding tasks, they are sensitive to errors due
to strong habitual processing, inappropriate reactions to
changes as well as resistance to change. In contrast to this,
knowledge-based tasks generate errors through excessive
demand and stress, as well as lack of knowledge or awareness
of the consequences. Errors occurring in skill-based tasks are
mainly Bslips^ or Blapses,^ coming from a correct intention
but a failure when carrying out the task, while Bmistakes^
arise from an incorrect intention leading to a wrong sequence
of activities due to application of an inappropriate rule or lack
of knowledge (22). In the typical situation, many patients may
need to take several drugs at the same moment, which raises
the level of demand from skill-based to more rule- or
knowledge-based tasks. With the varying health literacy of
patients (23), the effective delivery of the relevant product
information to the patient is a critical part of a patient centric
pharmaceutical drug product design and has to be looked at
from different patient characteristics (24,25). The patient’s
general physician, medical doctor, pharmacist, nurse, or
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professional caregiver all play a key role in selecting the most
suited pharmaceutical drug product to assure the optimal
interaction between the patient and the product that ensures
safe drug product administration and effective therapy. This
includes an integral approach to formulation development,
which also takes account of product access, reimbursement,
etc. The prescription of patient centric products will have to
take into account the concurrent use of other products to
reduce the risk of confusion. Finally, frequent monitoring of
the patient’s behavior is required in order to provide essential
and continuing education and assurance that the drug product
is being used as intended.
The European Medicines Agency (EMA) deﬁnes a drug
product as Ba pharmaceutical preparation in its container
closure system, together with any measuring and administra-
tion device and the authorized written user instructions
(SmPC section 6, package leaﬂet, product label).^ This
deﬁnition is extended by additional terms specifying the
preparation as being Ba formulation in a particular strength/
concentration,^ or in case of formulations for single use, the
labeled container contents and a formulation as being Bthe
composition of a particular dosage form.^ Although not
speciﬁed, the formulation also entails the product appear-
ance. Furthermore, the EMA provides a deﬁnition of
Bpharmaceutical design of a drug (medicine)^ as Bthe
composition, dosage form, route of administration, dosing
frequency, packaging, measuring or administration device and
the user instruction of a medicine.^ The currently proposed
deﬁnitions are in agreement with those of the EMA, yet they
provide a stronger emphasis on the interaction between the
patient and the drug product.
The closest regulatory deﬁnition combining product and
patient aspects is the deﬁnition used for Bage appropriate
paediatric drug (medicine)^ which is Ba drug (medicine),
whose pharmaceutical design makes it suitable for use in the
target age group(s)^ (26). This deﬁnition, however, focuses on
the product usability. However, the deﬁnition does not make
clear if the suitability of use would also relate to the entire
patient-product interface that should assure the intended and
correct use, including prevention of non-adherence
(intentional) or medication errors (unintentional).
There is no clear deﬁnition for patient centricity even
though the words are used in several contexts. The common
theme is that patient centric means the involvement of the
patient in the healthcare process. The FDA uses patient
centricity as a term in conjunction with BPatient Reported
Outcomes,^ which aims to get patient feedback on the beneﬁt
to risk of a new drug substance in the development process
and the perceived value for the patient (27). The deﬁnition
proposed by the authors puts patient centricity in the context
of the pharmaceutical drug product design, through the direct
involvement of the patients in the conceptual phase of the
development of the drug and the re-evaluation of the drug’s
pharmaceutical design during the marketing phase for
potential product enhancements during the product life cycle.
In principle, the development of a patient centric drug
product may follow similar processes as being used for the
development of medical devices or healthcare environments
(28,29). This would include a user and use environment
proﬁling, cognitive walkthrough and task analysis, risk
analysis as well as usability testing in the concerned patient
population. The process targets to identify product-related
sources of medication errors or issues that would have an
impact on drug product safety and effectiveness. For example,
a drug product that needs to be taken in the fasted state at
least half an hour before breakfast has a high likelihood in
certain patients to be taken after breakfast along with the
other medications unless the drug product is designed in a
way that Bforces^ patients to an administration before
breakfast. Valuable information on product characteristics
and how they relate to the patient-product interaction can be
generated from other methodologies applied during drug
product design and development. Leveraging information
from product design studies incorporating multiple proto-
types, as well as subsequent usability and human factors
studies will undoubtedly result in improved products for
patients and caregivers. Patient-reported outcome (PRO)
studies, aiming to capture patient feedback on the
perception and experience with a drug treatment in the
relevant disease (30,31) is an emerging area of focus that will
increasingly provide greater insight into product design.
Ethnography (32) and ergonomic research (33) are other
tools that can be used during the development of pharma-
ceutical products. The consumer healthcare industry has a
tradition in involving consumers and patients in the drug
product development process through patient testing and
consumer surveys (34), and the consumer industry in general
has introduced Bdesign thinking^ as a process to better
address the consumer needs in product design (35,15).
Technical speciﬁcations and standards exist for testing the
ease of opening of consumer packaging (CEN/TS 15945) or
child resistance (ISO 8317:2015) that provide useful insight
into usability aspects. For pharmaceutical applications, tradi-
tional customer centric approaches may need to be adapted
to provide greater relevance to the speciﬁc needs of the
patient population for a given product. Additional valid
methods are required and might be developed based in the
existing methods and the learnings from other industries to
provide the necessary comparison between and evidence for
patient centric drug product design.
This approach to achieving a patient centric pharmaceu-
tical drug product design is also in agreement with the
principles used for establishing patient safety in healthcare
environment (36), and FDA’s quality by design approach for
enhanced product and process understanding leading to the
development of pre-deﬁned drug products with desired
therapeutic outcomes (12). US FDA has long recognized that
quality cannot be tested into compliance of a drug product,
and the drug product needs to have a well-deﬁned target
product proﬁle with speciﬁc patient need documentation
ahead of product development. This strategy ensures that
the drug product and process are well understood to
consistently deliver the pre-deﬁned performance to the
speciﬁc patient population. Therefore, the regulatory prece-
dence for patient centric dosage forms is in place, although it
is not well deﬁned and promoted. One such example of a
patient centric dosage forms for geriatric use is the approval
of 3D printed Spritam® tablet dosage forms that are designed
for easy swallowability of even up to 1250-mg dose of
levetiracetam. This drug product was approved by US FDA
in August 2015. Spritam® tablets disintegrate within seconds
when taken with a sip of water, to provide medication in an
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easily swallowable mass in the mouth of geriatric patients, or
even other patients that have difﬁculty in swallowing. Taking
into account that expressions of many age- and disease-
related design drivers and design inputs are similar, it can be
hypothesized that the design outputs will serve several patient
populations as well as not exclude any patients with less
severe expressions. This means that patient centric pharma-
ceutical drug product design will become self-evident, make
the products more universal, and eventually, provide im-
proved standards. These expected outcomes will lead to
enlarged rather than restricted patient populations that
beneﬁt from such patient centric design.
It should be noted that patient centricity might also
include quality aspects mainly required for industrial and
regulatory purposes, but that may not be a direct need for
the patient. For example, a 2–5-year stability of the drug
product is commonly targeted to assure the industrial
supply chain and hence patient access to the drug product.
However, a patient would only require product stability
during the time of product receipt and treatment duration,
which is normally no longer than 3 months for in-use
conditions. In this respect, a long shelf life remains
primarily a supply chain need and not a direct need of
the patient even though the patient might beneﬁt indirectly from
a long shelf life.
CONCLUSION
Drug products are becoming increasingly diverse
whereas the therapeutic dosing regimens that have to be
adopted by the main users of drugs may become rather
complex. In order to adequately address medication manage-
ment in future drug therapies, the interface between a drug
product and an individual patient has to be considered a
critical part of product quality and an important condition to
the drug’s intended use and hence its beneﬁt to risk proﬁle. A
patient centric drug product aims to reduce medication errors
while improving the medicine’s effectiveness through a user-
centered product design of the portfolio of drug products that
is based on a prediction and subsequent evaluation of the
interface of the patient or caregiver with the product that is
mainly intended to serve the needs of this patient. For the
future scientiﬁc research in this area, it is important to have a
clear deﬁnition of patient centric pharmaceutical drug prod-
uct design and its implementation in drug product develop-
ment. The current publication can be used as a basis for
further discussions among the relevant stakeholders. It may
further highlight the need to better inform patients, care-
givers, and healthcare professionals on the characteristics of
the drug products in the overall drug portfolio and the
advantages and disadvantages associated with the use of any
such product.
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